HTA Regulation (HTAR)

What is the HTAR?

The Health Technology Assessment Regulation (HTAR) in Europe is a significant piece of legislation to enhance cooperation and harmonisation among European Union (EU) member states regarding health technology assessment. The HTAR is designed to create a structured and transparent framework for the assessment of health technologies, including pharmaceuticals, medical devices, and other health interventions, across the EU.

Key features of the HTAR

Harmonised Methodology

• The HTAR establishes a common set of methodological standards for conducting HTAs. This includes guidelines on clinical assessments, cost-effectiveness analyses, and other aspects of technology evaluation.
• By standardising methodologies, the HTAR aims to ensure consistency and comparability of HTA results across member states.

Joint Clinical Assessments

• One of the core elements of the HTAR is the introduction of joint clinical assessments (JCAs) for certain health technologies, particularly for pharmaceuticals and high-risk medical devices.
• JCAs are conducted at the EU level, and the results are intended for use by all member states, reducing duplication of efforts and speeding up the decision-making process.

Coordination Group

• The HTAR establishes a Coordination Group composed of representatives from national HTA bodies. This group is responsible for overseeing the implementation of the regulation and ensuring effective cooperation between member states.
• The Coordination Group plays a crucial role in selecting technologies for joint assessments and in developing and updating methodological guidelines.

Scientific Advice

• The HTAR provides for the possibility of obtaining scientific advice from the European Medicines Agency (EMA) and other relevant bodies. This advice can help guide the assessment process and ensure evaluations are based on the latest scientific evidence.
• Scientific advice is particularly important for ensuring that the clinical development plans of new health technologies align with HTA requirements.

Stakeholder Involvement:

• The HTAR emphasises the importance of involving various stakeholders, including patients, healthcare professionals, and industry representatives, in the HTA process.
• Stakeholder involvement is intended to ensure that the assessments are comprehensive and consider the perspectives of those directly affected by the evaluated technologies.

Transparency and Public Access:

• The HTAR mandates that the results of joint clinical assessments and other HTA activities be publicly available. This transparency promotes trust in the assessment process and enables informed decision-making by patients and healthcare providers.
• Public access to HTA reports and related information also facilitates the dissemination of best practices and supports evidence-based healthcare.

Implementation and transition period:

• The HTAR includes provisions for a transition period to allow member states and stakeholders to adapt to the new requirements. This period is intended to ensure the regulation’s smooth implementation and address any challenges that may arise.
• During the transition period, the European Commission and the Coordination Group will work closely with national HTA bodies to build capacity and establish the necessary infrastructure for joint assessments.

Objectives and benefits of the HTAR

The HTAR aims to achieve several key objectives, including:

• Improving Access to Innovative Health Technologies: By streamlining and harmonising the HTA process, the HTAR seeks to accelerate the availability of new health technologies to patients across the EU.
• Supporting Informed Decision-Making: By providing high-quality, evidence-based information, the HTAR aims to support informed decision-making by national authorities, healthcare providers, and patients.
• Enhancing Efficiency and Reducing Duplication: Joint clinical assessments and other cooperative activities under the HTAR are intended to reduce duplication of efforts and optimise resources.
• Promoting Equity in Healthcare: The harmonised approach to HTA under the HTAR is expected to contribute to more equitable access to health technologies and reduce disparities in healthcare across member states.

Challenges and considerations

While the HTAR represents a significant step forward in European HTA cooperation, it also presents several challenges and considerations:

• Implementation Challenges: The transition to a harmonised HTA framework requires significant effort and coordination among national HTA bodies, the European Commission, and other stakeholders. Ensuring that all parties are adequately prepared and resourced is crucial for successful implementation.
• Balancing National and EU-Level Assessments: While the HTAR promotes joint assessments, it also recognises the importance of national HTA activities. Striking the right balance between EU-level and national assessments is essential for addressing the specific needs and contexts of individual member states.
• Ensuring Methodological Rigor: Maintaining high methodological standards and ensuring the scientific rigour of joint clinical assessments is critical for the credibility and reliability of the HTA process.
• Engaging Stakeholders: Effective stakeholder engagement is vital for the success of the HTAR. Ensuring that the perspectives of patients, healthcare providers, and industry representatives are adequately considered is essential for comprehensive and balanced assessments.

Conclusion

The Health Technology Assessment Regulation (HTAR) represents a landmark initiative in the EU to enhance cooperation, harmonisation, and efficiency in assessing health technologies. By establishing a common framework for HTA, promoting joint clinical assessments, and ensuring transparency and stakeholder involvement, the HTAR seeks to improve access to innovative health technologies and support evidence-based decision-making across the EU.

The successful implementation of the HTAR will depend on the collaborative efforts of national HTA bodies, the European Commission, and other stakeholders. As the HTAR framework is put into practice, it has the potential to significantly impact the landscape of health technology assessment in Europe, ultimately contributing to better health outcomes and more equitable healthcare for all EU citizens.

Resources